Sitting on a Cash Pile 17.0? Focus on Killer Viruses
Cidara Therapeutics, Inc. (NASDAQ:CDTX) broke out on 20 August at 1.96 and confirmed on 22 September at 2.24/share. Thus triggering an LTN Cash Pile Buy signal with a 1yr price target at 6.80/share.
The Key support is at 2.14 and the Key resistance is at 2.46. Our overall outlook is Bullish to Very Bullish in here as Key technical indicators are flashing Very Bullish.
Cidara Therapeutics is a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States.
The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
Cidara Therapeutics, Inc. was incorporated in Y 2012 and is HQ'd in San Diego, California.
Have a prosperous day, Keep the Faith!
Palantir Stock (PLTR): BUY Rating, $250 Price Target — The 40% Dislocation
Palantir is down ~40% in 2026 even as Q1 revenue grew 85% and management guided FY2026 to $7.66B. Shayne Heffernan issues a BUY on PLTR with a $250 price target — full breakdown of the business, customers, five-year revenue, every major Wall Street bank target and the corporate outlook.
Larry Fink Called It. CME Just Made It Real. The Compute Futures Market Has Arrived
The Quantum-AI Convergence Is Real. The Quantum Stocks Aren't the Trade.
China’s Economic Resilience
Every story, signed and delivered.
Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.